SANTA CLARA, Calif., June 23, 2011 /PRNewswire/ — NewCardio,
Inc., (OTC BB: NWCI) a cardiac diagnostic technology provider,
announced today that Patrick
Maguire, MD, PhD, member of the NewCardio board of directors
since March of 2008 and a proven leader and a seasoned executive
with experience in a variety of leadership roles with companies
involved in medical devices and pharmaceuticals, has been
elected Chairman of NewCardio’s Board of Directors, effective
immediately. Mark W. Kroll, PhD, FACC, FHRS, NewCardio’s previous
chairman, will remain a director.
Maguire has served as the Chief Executive Officer and President
of CyberHeart Inc.
since 2006. He joined CyberHeart following the
acquisition of the oncology assets of Targent Incorporated, where
Dr. Maguire served as President, CEO, and Director since 2002.
Prior to joining Targent, Dr. Maguire was Vice President of Medical
Affairs and Technology Development at VitaGen Incorporated, where
he oversaw the preparation of IND’s, NDA’s, and IDE’s and managed
VitaGen’s clinical trials in acute and chronic liver failure as
well as medical and industry collaborations. He is a cardiovascular
and thoracic surgeon and has acted as a principal investigator for
medical devices and associated clinical trials. Dr. Maguire is a
fellow of the American and Royal College of Surgeons and a member
of more than 20 medical, academic and business societies. He
received an AB degree from Wesleyan University, an MD and PhD
(Physiology and Biophysics) degrees from Georgetown University and
an MBA degree from Pepperdine University. He completed surgical and
cardiovascular fellowships at The Peter Bent Brigham Hospital,
Harvard University, and Stanford University.
Dr. Maguire commented, “